These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37741703)

  • 1. Rapid detection of telomerase expression of neuroblastoma in paraffin-embedded tissue: combination of in situ hybridisation and quantitative PCR.
    Zhao M; Guan Z; Gong L; Liu F; Gu W; Liu L; Jiang K; Cai J; Feng C; Kuick CH; Chang KTE; Wang J; Tang H; Yin M; Mao J
    Pathology; 2023 Dec; 55(7):958-965. PubMed ID: 37741703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
    Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
    Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
    Koneru B; Lopez G; Farooqi A; Conkrite KL; Nguyen TH; Macha SJ; Modi A; Rokita JL; Urias E; Hindle A; Davidson H; Mccoy K; Nance J; Yazdani V; Irwin MS; Yang S; Wheeler DA; Maris JM; Diskin SJ; Reynolds CP
    Cancer Res; 2020 Jun; 80(12):2663-2675. PubMed ID: 32291317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres.
    Graham MK; Xu B; Davis C; Meeker AK; Heaphy CM; Yegnasubramanian S; Dyer MA; Zeineldin M
    Cancer Res Commun; 2024 Jun; 4(6):1533-1547. PubMed ID: 38837897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
    Akter J; Kamijo T
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.
    Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E
    J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma.
    Roderwieser A; Sand F; Walter E; Fischer J; Gecht J; Bartenhagen C; Ackermann S; Otte F; Welte A; Kahlert Y; Lieberz D; Hertwig F; Reinhardt HC; Simon T; Peifer M; Ortmann M; Büttner R; Hero B; O'Sullivan RJ; Berthold F; Fischer M
    JCO Precis Oncol; 2019 Dec; 3():1-20. PubMed ID: 35100718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN amplification, TERT rearrangements and ATRX mutations in neuroblastoma: clinicopathological correlates- an Indian perspective.
    Kerkar AN; Chinnam D; Verma A; Peters NJ; Kakkar N; Trehan A; Singh M; Gupta K
    Virchows Arch; 2023 Oct; 483(4):477-486. PubMed ID: 37460674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promotor region rearrangements analyzed in high-risk neuroblastomas by FISH method and whole genome sequencing.
    Kawashima M; Ueda Y; Kurihara S; Hiyama E
    Int J Clin Oncol; 2020 Dec; 25(12):2166-2174. PubMed ID: 32894394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliable assessment of telomere maintenance mechanisms in neuroblastoma.
    Meeser A; Bartenhagen C; Werr L; Hellmann AM; Kahlert Y; Hemstedt N; Nürnberg P; Altmüller J; Ackermann S; Hero B; Simon T; Peifer M; Fischer M; Rosswog C
    Cell Biosci; 2022 Sep; 12(1):160. PubMed ID: 36153564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
    Nakazawa A
    Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples.
    Somasundaram DB; Aravindan S; Yu Z; Jayaraman M; Tran NTB; Li S; Herman TS; Aravindan N
    BMC Cancer; 2019 Jan; 19(1):106. PubMed ID: 30691436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational practice of fluorescence in situ hybridisation to identify neuroblastic tumours with TERT rearrangements.
    Yu Y; Zhang M; Yao X; Guan X; Jia C; Chu P; Zhang R; Yang Y; Jin Y; Wang H; Ni X; He L; Guo Y
    J Pathol Clin Res; 2023 Nov; 9(6):475-487. PubMed ID: 37608330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues.
    Poremba C; Scheel C; Hero B; Christiansen H; Schaefer KL; Nakayama Ji; Berthold F; Juergens H; Boecker W; Dockhorn-Dworniczak B
    J Clin Oncol; 2000 Jul; 18(13):2582-92. PubMed ID: 10893290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma.
    George SL; Parmar V; Lorenzi F; Marshall LV; Jamin Y; Poon E; Angelini P; Chesler L
    J Exp Clin Cancer Res; 2020 May; 39(1):78. PubMed ID: 32375866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
    Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
    Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors.
    Valentijn LJ; Koster J; Zwijnenburg DA; Hasselt NE; van Sluis P; Volckmann R; van Noesel MM; George RE; Tytgat GA; Molenaar JJ; Versteeg R
    Nat Genet; 2015 Dec; 47(12):1411-4. PubMed ID: 26523776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence in situ hybridization (FISH) detection of MYCN oncogene amplification in neuroblastoma using paraffin-embedded tissues.
    Misra DN; Dickman PS; Yunis EJ
    Diagn Mol Pathol; 1995 Jun; 4(2):128-35. PubMed ID: 7551293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of TERT mRNA expression using RNAscope®: A potential histopathologic diagnostic and prognostic tool.
    Momeni-Boroujeni A; Yousefi E; Gupta S; Benayed R; Berger MF; Ladanyi M; Monroe R; Kim J; Jungbluth A; Weigelt B; Park KJ
    Pathol Res Pract; 2022 May; 233():153892. PubMed ID: 35439652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections.
    Tsai HY; Hsi BL; Hung IJ; Yang CP; Lin JN; Chen JC; Tsai SF; Huang SF
    Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.